Morcos Nadia Ys, Zakhary Nadia I, Said Mahmoud M, Tadros May Mm
Biochemistry Department, Faculty of Science, Ain Shams University, Egypt.
Ecancermedicalscience. 2013 Apr 15;7:305. doi: 10.3332/ecancer.2013.305. Print 2013.
The present study was undertaken to identify patient populations at high risk for bone metastases (BM) at any time after diagnosis of operable breast cancer.
A total number of 59 cases with breast cancer after mastectomy was subdivided into two main groups that included 30 patients with radiologically confirmed BM and 29 patients with no bone metastasis (NBM). Patients with NBM were formerly observed for a one-year follow-up interval to monitor the development of bone metastasis (new BM). Parameters included a full blood picture, tumour markers (carcinoembryonic antigen and CA 15.3) and some biochemical markers (vascular endothelial growth factor and zinc levels, as well as tartrate-resistant acid phosphatase and alkaline phosphatase activities).
A significant elevation was recorded in carcinoembryonic antigen level and alkaline phosphatase activity, as well as inflammation and vascularisation markers at the time of primary diagnosis in patients with BM, compared with those without BM. CA 15.3 was significantly higher in the new BM group as compared with the other two groups (patients free of bone metastasis [free BM] and BM). According to the likelihood ratio, a panel of single, calculated as well as combined markers was proposed to predict BM within one year in breast cancer patients.
Vascularisation and inflammation markers, as well as CA 15.3 are predictive of bone recurrence within one year in breast carcinoma patients. We suggest that in cancer validation studies it is imperative to search for markers that link to the premetastatic process and to determine what type of mechanism is active in each stage.
本研究旨在确定可手术乳腺癌诊断后任何时间发生骨转移(BM)的高危患者群体。
59例乳腺癌乳房切除术后患者被分为两个主要组,其中30例经放射学证实有骨转移,29例无骨转移(NBM)。对NBM患者进行为期一年的随访,以监测骨转移(新的BM)的发生情况。参数包括全血细胞计数、肿瘤标志物(癌胚抗原和CA 15.3)以及一些生化标志物(血管内皮生长因子和锌水平,以及抗酒石酸酸性磷酸酶和碱性磷酸酶活性)。
与无BM的患者相比,BM患者在初次诊断时癌胚抗原水平、碱性磷酸酶活性以及炎症和血管生成标志物均显著升高。新的BM组的CA 15.3显著高于其他两组(无骨转移[无BM]患者和BM患者)。根据似然比,提出了一组单一、计算得出以及组合的标志物,用于预测乳腺癌患者一年内的BM情况。
血管生成和炎症标志物以及CA 15.3可预测乳腺癌患者一年内的骨复发情况。我们建议在癌症验证研究中,必须寻找与转移前过程相关的标志物,并确定每个阶段活跃的机制类型。